In Brief: Medtronic
Medtronic: SynchroMed pump using Ciba-Geigy's Lioresal (baclofen) Intrathecal receives FDA clearance for Treatment Protocol in the control of spasticity of cerebral origin, including spastic cerebral palsy and severe spasticity related to head trauma. The drug-device combo has been marketed since October 1992 for spasticity in patients with spinal cord lesions or multiple sclerosis. Medtronic estimates there are 35,000 cerebral palsy patients in the U.S. who might benefit from the therapy. Under the Treatment Protocol, Medtronic charges for the SynchroMed pump, which lists for about $7,000, but will provide the drug free...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth